SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs) ...
Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – ...
(RTTNews) - Next Cure Inc. (NXTC) outlined steady clinical and operational momentum across its two antibody-drug conjugate programs while reporting a preliminary year-end cash position that supports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results